表紙
市場調査レポート

世界における治療用ワクチン市場の予測

Global Therapeutic Vaccines Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 298803
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
世界における治療用ワクチン市場の予測 Global Therapeutic Vaccines Market 2014-2018
出版日: 2014年03月28日 ページ情報: 英文 54 Pages
概要

現在市場には、ProvengeとOncophageという、2つの癌治療用ワクチンが存在しています。さらに、多くの治療用ワクチンが臨床開発中であり、これらは、今後数年内に認可される見通しです。世界の治療用ワクチン市場は、2013年から2018年にかけて、62.81%の複合年間成長率(CAGR)で拡大する事が見込まれています。

当レポートでは、世界における治療用ワクチン市場の現況と成長の見通し、成長因子と課題、主要ベンダーの情報などを提供しており、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 地理区分

第8章 主要国

  • 米国

第9章 購入基準

第10章 市場成長因子

第11章 成長因子とその影響

第12章 市場の課題

第13章 成長因子と課題の影響

第14章 市場動向

第15章 動向とその影響

第16章 パイプライン分析

第17章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • その他の有力ベンダー

第18章 主要ベンダーの分析

  • Agenus Inc.
  • Bavarian Nordic A/S
  • Dendreon Corp.
  • GlaxoSmithKline plc
  • Novartis International AG

第19章 その他のレポート

目次
Product Code: IRTNTR3441

About Therapeutic Vaccines

A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual with a disease in order to induce a defense mechanism. There are two approved cancer therapeutic vaccines on the market; Provenge and Oncophage. Additionally, a large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period.

TechNavio's analysts forecast the Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Therapeutic Vaccine market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapeutic vaccines available in the market.

TechNavio's report, the Global Therapeutic Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Therapeutic Vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Agenus Inc.
  • Bavarian Nordic A/S.
  • Dendreon Corp.
  • GlaxoSmithKline plc
  • Novartis International AG

Other Prominent Vendors

  • AFFiRiS AG.
  • Argos Therapeutics Inc.
  • Celldex Therapeutics Inc.
  • CEL-SCI Corp.
  • Cytos Biotechnology AG
  • GlobeImmune Inc.
  • NewLink Genetics Corp.
  • NovaRx Corp.
  • Oncothyreon Inc.
  • TVAX Biomedical Inc.
  • TapImmune Inc.
  • Vical Inc.
  • Vaccinogen Inc.

Market Driver

  • Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders
  • Ongoing Development of a Large Number of Therapeutic Vaccines

Market Challenge

  • Stringent Regulations
  • Adverse Side Effects of Therapeutic Vaccines

Market Trend

  • Improved Understanding of Immunology and Immunotherapy
  • Increase in Mergers and Acquisitions

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Geographical Segmentation

08. Key Leading Countries

  • 08.1. USA

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Pipeline Analysis

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Agenus Inc.
    • 18.1.1. Business Overview
    • 18.1.2. Key Information
    • 18.1.3. SWOT Analysis
  • 18.2. Bavarian Nordic A/S
    • 18.2.1. Business Overview
    • 18.2.2. Business Segmentation
    • 18.2.3. Key Information
    • 18.2.4. SWOT Analysis
  • 18.3. Dendreon Corp.
    • 18.3.1. Business Overview
    • 18.3.2. Key Information
    • 18.3.3. SWOT Analysis
  • 18.4. GlaxoSmithKline plc
    • 18.4.1. Business Overview
    • 18.4.2. Business Segmentation
    • 18.4.3. Key Information
    • 18.4.4. SWOT Analysis
  • 18.5. Novartis International AG
    • 18.5.1. Business Overview
    • 18.5.2. Business Segmentation
    • 18.5.3. Key Information
    • 18.5.4. SWOT AnalysisOther Reports in the Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Therapeutic Vaccines Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Therapeutic Vaccines Market by Geographical Segmentation 2013
  • Exhibit 4: Segmentation of Therapeutic Vaccines under Clinical Trial, by Disease 2013
  • Exhibit 5: Segmentation of Therapeutic Vaccines under Clinical Trial by Type of Cancer 2013
  • Exhibit 6: Segmentation of Therapeutic Vaccines under Clinical Trial by Type of Tropical Infectious Disease 2013
  • Exhibit 7: Segmentation of Therapeutic Vaccines under Clinical Trial, By Physiological Disorders 2013
  • Exhibit 8: Late Stage Pipeline Analysis of Therapeutic Vaccines 2013
  • Exhibit 9: Business Segmentation of Bavarian Nordic A/S
  • Exhibit 10: Business Segmentation of GlaxoSmithKline plc
  • Exhibit 11: Business Segmentation of Novartis International AG
Back to Top